This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the Potential of Insmed's ARIKAYCE in the front line setting for NTM/MAC Lung Disease
Ticker(s): INSMWho's the expert?
Institution: Stanford
- Medical Director, Stanford Medical Center Respiratory Care Services where he specializes in both critical care medicine and pulmonary medicine.
- Directs the NTM clinical program at Stanford which manages 200 patients, vast majority have MAC infections.
- Site PI for both the INS-212 and INS-312 trials; clinical focus on the treatment of chronic bronchiectasis and mycobacterial lung infections, and also on rare lung diseases, including lymphangioleiomyomatosis (LAM).
Interview GoalThis conversation will focus on the treatment landscape and potential use of Arikayce for patients ith NTM/MAC.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
